Andreas Mueller - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Andreas Mueller's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Andreas Mueller
Verified
Editor, superfuture
Amsterdam
Beats
Content
Increased circulating Endothelin-1 is a risk factor for ECMO use and mortality in neonates with congenital diaphragmatic hernia: a prospective observational study | Respiratory Research | Full Text
By De Vadder, Bartolomeo Bo, Neil Patel, Stefan Holdenrieder, Andreas Mueller, Florian Kipfmueller, Lotte Lemloh, Aster de Vadder, Tamene Melaku| Respiratory Research Verified We performed a prospective single-center (University Hospital of Bonn) subgroup analysis of CDH newborns born between 2014 and 2022, who were initially enrolled in the “Biomarker forOutcomePredictionin Neonates withCongenital Diaphragmatic Hernia” (BIOPTIC) study (Clinical trial registration with German Clinical Trial Register (DKRS), trial registration number: DKRS00034329; Registration date: 24.05.2024).
By Andreas Mueller, Kathleen Klinge, Gerhard Foerster, Fabian Burk| Wiley Online Library Verified 1 Introduction Unilateral vocal fold paralysis (UVFP) with a persistent glottal gap limits the quality of life due to severe dysphonia and has a significant impact on a patient's daily communication [1]. If there is no compensation supported by voice therapy, all available interventions are aimed at improving glottic closure.
Increased circulating Endothelin-1 is a risk factor for ECMO use and mortality in neonates with congenital diaphragmatic hernia: a prospective observational study | Respiratory Research | Full Text
By De Vadder, Bartolomeo Bo, Neil Patel, Stefan Holdenrieder, Andreas Mueller, Florian Kipfmueller, Lotte Lemloh, Aster de Vadder, Tamene Melaku| Respiratory Research Verified We performed a prospective single-center (University Hospital of Bonn) subgroup analysis of CDH newborns born between 2014 and 2022, who were initially enrolled in the “Biomarker forOutcomePredictionin Neonates withCongenital Diaphragmatic Hernia” (BIOPTIC) study (Clinical trial registration with German Clinical Trial Register (DKRS), trial registration number: DKRS00034329; Registration date: 24.05.2024).
Company Info
superfuture
Welcome to the Super Future Technology Community! Super Future is a trusted investment company that was founded in 2019 that recently launched in Dubai. We provide personalized support to investors who want to maximize their returns in the global market using 21st century machine learning technology. With offices in Chicago, India, China, South Korea, SEA, and the MENA region, Super Future has a global reach and a team of skilled experts who use advanced trading software to provide trading services for institutional investors. We'd love connect with you on our social platforms here: https://linktr.ee/superfuturetechnology For any enquiries you can contact us at: marketing@supfut.online
Amsterdam, Netherlands
+971 4 609 0821
Founded: 2019